BioDirIntellia Therapeutics
Intellia Therapeutics advances in vivo and ex vivo CRISPR/Cas9 genome editing therapies for genetic diseases. Tailored for modern biology and life science teams.
AI 核心摘要 / 关键看点
| Pricing Model | Clinical-stage biotech company rather than a general research product. |
| Official Website | www.intelliatx.com → |
| Primary Category | Cell & Gene Therapy |
资源简介
## Overview
Intellia Therapeutics advances in vivo and ex vivo CRISPR/Cas9 genome editing therapies for genetic diseases. Tailored for modern biology and life science teams.
## Key Highlights
- First-in-human in vivo CRISPR therapies targeting transthyretin amyloidosis.
- Collaborations with Regeneron and Novartis on liver and hematology programs.
- Pipeline spanning autoimmune, oncology, and rare diseases.
## Ideal For
- Clinicians evaluating emerging genome editing treatments
- Biotech teams partnering on CRISPR technology platforms
- Regulators and payers monitoring CRISPR clinical milestones
## Quick Links
- Official site: [intelliatx.com](https://www.intelliatx.com/)
- Add to BioDir collections to track updates and collaborators.
适用场景 / 优点
- Readers following clinical genome-editing companies
- Users looking for commercially significant gene-editing names
不适用场景 / 注意点
- Teams who only want platform-software options
Discovered on 6/29/2026